The Best Healthcare Stock to Hold in Uncertain Times

Source The Motley Fool

Key Points

  • GlaxoSmithKline is now known simply as GSK.

  • GSK stock trades for 13 times earnings and barely 11 times free cash flow.

  • The pharmaceutical giant pays a 3.3% dividend yield and is growing earnings in the high single digits.

  • 10 stocks we like better than GSK ›

As the U.S. emerges from its longest-ever government shutdown, tariffs continue to drag on the economy, inflation rates are heating up, and the Federal Reserve has resumed cutting interest rates to try to avoid the economy suffering a hard landing. Despite all this turmoil, the S&P 500 is trading near all-time highs, and the Shiller price-to-earnings (P/E) ratio of the index (which measures 10-year average earnings) sits above 40x -- approaching the valuation of the stock market just before the internet bubble burst in 2000.

In such uncertain times, investors seek safety and value in their stocks -- but where can you find it?

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »

Chalkboard drawing of a risk dial shows low risk.

Image source: Getty Images.

Introducing GSK

Historically, healthcare has been a steady performer precisely because it's a product that everyone is going to need eventually. If you ask me, GSK (NYSE: GSK), the pharmaceutical giant formerly known as GlaxoSmithKline, is just the kind of healthcare stock you should be considering.

A strong performer already, GSK stock is trading up 44% in 2025, yet its stock remains a good bargain. GSK trades for a reasonable P/E ratio of just 13 and is the second-least expensive (by P/E) of the eight big international drug stocks. Yet, GSK generates so much cash from its business that its price-to-free-cash-flow ratio is just 11.1.

Analysts polled by S&P Global Market Intelligence believe GSK can grow its annual earnings by 8% on average over the next five years, and the stock pays a very respectable 3.3% dividend yield. At an expected total return ratio of less than 1.0, GSK stock looks like a buy to me.

Should you invest $1,000 in GSK right now?

Before you buy stock in GSK, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and GSK wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $624,230!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,187,967!*

Now, it’s worth noting Stock Advisor’s total average return is 1,069% — a market-crushing outperformance compared to 195% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.

See the 10 stocks »

*Stock Advisor returns as of November 10, 2025

Rich Smith has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends S&P Global. The Motley Fool recommends GSK. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Why a Quiet 2025 Signals a Massive 2026 Crypto Bull Run: Bitwise CIO ExplainsBitwise's Matt Hougan Predicts a Crypto Boom in 2026 Amid Current Market Struggles
Author  Mitrade
Yesterday 04: 03
Bitwise's Matt Hougan Predicts a Crypto Boom in 2026 Amid Current Market Struggles
placeholder
Bitcoin vs. Ethereum: Distinct Monetary UniversesBitcoin and Ethereum are diverging significantly in their monetary roles, according to a joint report from Glassnode and Keyrock.
Author  Mitrade
11 hours ago
Bitcoin and Ethereum are diverging significantly in their monetary roles, according to a joint report from Glassnode and Keyrock.
placeholder
Ethereum slides 5% as bears lean on $3,500 cap and put $3,150 support in focusEthereum (ETH) drops more than 5% after a failed push above $3,550, with price sliding to $3,153 and now holding below $3,350, the 100-hour SMA and a bearish trend line at $3,500; unless bulls reclaim the $3,350–$3,500 zone, the short-term bias stays bearish and a clean break under $3,150 could expose $3,050, $3,000 and even the $2,880–$2,850 support area.
Author  Mitrade
10 hours ago
Ethereum (ETH) drops more than 5% after a failed push above $3,550, with price sliding to $3,153 and now holding below $3,350, the 100-hour SMA and a bearish trend line at $3,500; unless bulls reclaim the $3,350–$3,500 zone, the short-term bias stays bearish and a clean break under $3,150 could expose $3,050, $3,000 and even the $2,880–$2,850 support area.
placeholder
Gold Posts Biggest Weekly Gain in a Month as US Data Delays Fuel UncertaintyGold climbed higher on Friday, marking its strongest weekly performance in a month, as traders weighed the impact of a data backlog following the end of the US government's extended shutdown. Silver also moved upward.
Author  Mitrade
8 hours ago
Gold climbed higher on Friday, marking its strongest weekly performance in a month, as traders weighed the impact of a data backlog following the end of the US government's extended shutdown. Silver also moved upward.
placeholder
Top 3 Price Prediction: Bitcoin, Ethereum, Ripple – BTC, ETH, and XRP flash deeper downside risks as market selloff intensifiesBitcoin (BTC), Ethereum (ETH) and Ripple (XRP) trade in red on Friday after correcting more than 5%, 10% and 2%, respectively, so far this week.
Author  FXStreet
5 hours ago
Bitcoin (BTC), Ethereum (ETH) and Ripple (XRP) trade in red on Friday after correcting more than 5%, 10% and 2%, respectively, so far this week.
goTop
quote